The article discusses how early-stage cancer patients often experience metastatic recurrence due to micrometastases, which are exploitable for anti-metastatic therapies that engage the immune system. Daily low-dose aspirin has been associated with reduced metastasis and cancer death rates, particularly in individuals with high levels of human leukocyte antigen class I. The effects of aspirin may stem from its impact on T cell immunity and platelet function, suggesting a promising treatment avenue for preventing cancer recurrence in affected patients.
Meta-analyses suggest that daily aspirin usage significantly reduces metastasis and mortality in early-stage cancer patients, pointing to its potential role in anti-metastatic therapies.
Aspirin shows a connection between immune response and cancer outcomes, especially in colorectal cancer that expresses high HLA class I levels, indicating its immune-modulating effects.
Collection
[
|
...
]